AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32000790 — intervention group
Group type: COMPARATOR
Intervention: Arm-specific treatment delivered by a physiotherapist (Control Group)
Number of subjects: 40
Study 34598780 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 312
Study 34598780 — intervention group
Group type: COMPARATOR
Intervention: Relaxation control
Number of subjects: 312
Study 34145016 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine plus usual care
Number of subjects: 0
Study 34145016 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin plus usual care
Number of subjects: 0
Study 34145016 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline plus usual care
Number of subjects: 0
Study 34145016 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 33319846 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal direct current stimulation (tsDCS)
Number of subjects: 14
Study 33319846 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 14
Study 36244828 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization of CA-125 after 1 cycle of chemotherapy (defined as ≤35 U/mL)
Number of subjects: 350
Study 36244828 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern of CA-125 change following chemotherapy cycle 1
Number of subjects: 350
Study 36244828 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent decline of CA-125
Number of subjects: 350
Study 36244828 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute nadir normal value of CA-125 (0–10 vs. 11–35 U/mL)
Number of subjects: 350
Study 33290346 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative scalp block combined with incision line infiltration
Number of subjects: 56
Study 33290346 — intervention group
Group type: COMPARATOR
Intervention: Postoperative scalp block combined with incision line infiltration
Number of subjects: 56
Study 33290346 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative scalp block
Number of subjects: 56
Study 33290346 — intervention group
Group type: COMPARATOR
Intervention: Postoperative scalp block
Number of subjects: 56
Study 33590715 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous serum eye drops (SEDs)
Number of subjects: 19
Study 33590715 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic serum eye drops (SEDs)
Number of subjects: 19
Study 33590715 — intervention group
Group type: COMPARATOR
Intervention: Comparison of autologous and allogeneic SEDs
Number of subjects: 19
Study 36501047 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic containing a mixture of Lactobacillus and Bifidobacterium and fructooligosaccharide for 8 weeks
Number of subjects: 40
Study 36501047 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 40
Study 36501047 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic
Number of subjects: 40
Study 34214475 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil
Number of subjects: 326
Study 34214475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study 32720190 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Bereavement Program (FBP)
Number of subjects: 152
Study 36068494 — intervention group
Group type: EXPERIMENTAL
Intervention: eptinezumab 100 mg or 300 mg, administered intravenously once every 12 weeks for up to two doses
Number of subjects: 1072
Study 36068494 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1072
Study 33257805 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent symptoms of dry eye
Number of subjects: 2045
Study 33257805 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear-film break-up time ≤ 10 s
Number of subjects: 2045
Study 33257805 — intervention group
Group type: EXPERIMENTAL
Intervention: Schirmer test score ≤ 5 mm
Number of subjects: 2045
Study 33257805 — intervention group
Group type: EXPERIMENTAL
Intervention: Meibomian gland disease
Number of subjects: 2045
Study 33257805 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescein staining of the cornea
Number of subjects: 2045
Study 36360813 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent Empowerment-Based Psychosocial Intervention
Number of subjects: 111
Study 36360813 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 111
Study 34980047 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment plus INSURE
Number of subjects: 184
Study 34980047 — intervention group
Group type: COMPARATOR
Intervention: INSURE only (Control)
Number of subjects: 184
Study 34269427 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational Emotive Occupational Health Coaching (REOHC) for 12 weeks
Number of subjects: 84
Study 36469686 — intervention group
Group type: EXPERIMENTAL
Intervention: Group singing (GS) intervention
Number of subjects: 149
Study 33961539 — intervention group
Group type: EXPERIMENTAL
Intervention: Message recommending vaccination at age 11–12
Number of subjects: 1263
Study 33961539 — intervention group
Group type: EXPERIMENTAL
Intervention: Message recommending fewer doses at age 11–12
Number of subjects: 1263
Study 33961539 — intervention group
Group type: EXPERIMENTAL
Intervention: Message recommending fewer doses before age 15
Number of subjects: 1263
Study 33961539 — intervention group
Group type: COMPARATOR
Intervention: No message
Number of subjects: 1263
Study 34181180 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First with Assertive Community Treatment (HF with ACT)
Number of subjects: 575
Study 34181180 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First with Intensive Care Management (HF with ICM)
Number of subjects: 575
Study 34181180 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 575
Study 35138577 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative analysis of randomized clinical trial (RCT) and observational study data
Number of subjects: 0
Study 35138577 — intervention group
Group type: COMPARATOR
Intervention: Randomized clinical trial (RCT)
Number of subjects: 0
Study 35138577 — intervention group
Group type: COMPARATOR
Intervention: Observational study data
Number of subjects: 0
Study 33617796 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (25 μg) with Foley catheter
Number of subjects: 215
Study 33617796 — intervention group
Group type: COMPARATOR
Intervention: Buccal misoprostol (25 μg) with Foley catheter
Number of subjects: 215
Study 32616595 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 54
Study 32616595 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 54
Study 32616595 — intervention group
Group type: EXPERIMENTAL
Intervention: SABR
Number of subjects: 54
Study 32616595 — intervention group
Group type: EXPERIMENTAL
Intervention: SABR and Surgery
Number of subjects: 54
Study 35548914 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality
Number of subjects: 5
Study 35548914 — intervention group
Group type: COMPARATOR
Intervention: Non-immersive and semi-immersive VR
Number of subjects: 5
Study 36177538 — intervention group
Group type: EXPERIMENTAL
Intervention: App use (intervention group)
Number of subjects: 33
Study 36177538 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 33538149 — intervention group
Group type: EXPERIMENTAL
Intervention: UVC-treated platelets
Number of subjects: 171
Study 32307568 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib
Number of subjects: 0
Study 32307568 — intervention group
Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 0
Study 36347833 — intervention group
Group type: EXPERIMENTAL
Intervention: MusicGlove
Number of subjects: 10
Study 36347833 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study 32062791 — intervention group
Group type: EXPERIMENTAL
Intervention: Revusiran 500 mg subcutaneously daily for 5 days followed by weekly doses
Number of subjects: 206
Study 32062791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 32062791 — intervention group
Group type: EXPERIMENTAL
Intervention: Revusiran
Number of subjects: 206
Study 35565955 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week personalized healthy eating, sleep hygiene, and physical activity program
Number of subjects: 125
Study 35565955 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 125
Study 32019354 — intervention group
Group type: EXPERIMENTAL
Intervention: Independently derived recommended strategies for managing bipolar II disorder
Number of subjects: 18
Study 35059912 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional aerosol box
Number of subjects: 16
Study 35059912 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified aerosol box
Number of subjects: 16
Study 35059912 — intervention group
Group type: COMPARATOR
Intervention: No aerosol box
Number of subjects: 16
Study 33570548 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage radiotherapy (sRT) with or without 2 years of bicalutamide
Number of subjects: 352
Study 33570548 — intervention group
Group type: COMPARATOR
Intervention: Bicalutamide
Number of subjects: 352
Study 36343030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular irradiation of blood (ILIB) combined with myofunctional exercises; active application of ILIB performed twice a week for 8 weeks.
Number of subjects: 46
Study 36343030 — intervention group
Group type: COMPARATOR
Intervention: Placebo ILIB combined with myofunctional exercises; application of placebo ILIB and an orofacial myofunctional therapy (MFT) exercise protocol.
Number of subjects: 46
Study 32117242 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized immunosuppression
Number of subjects: 59
Study 32117242 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 59
Study 32117242 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 59
Study 32673619 — intervention group
Group type: EXPERIMENTAL
Intervention: therapy with retreat possibility with conspecifics
Number of subjects: 20
Study 32673619 — intervention group
Group type: EXPERIMENTAL
Intervention: therapy with retreat possibility without conspecifics
Number of subjects: 20
Study 32673619 — intervention group
Group type: EXPERIMENTAL
Intervention: therapy without retreat possibility
Number of subjects: 20
Study 32673619 — intervention group
Group type: COMPARATOR
Intervention: setting without human interaction
Number of subjects: 20
Study 35695169 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-73763989 (200 mg every 4 weeks) + JNJ-56136379 (250 mg daily) + nucleos(t)ide analogue (NA)
Number of subjects: 66
Study 35695169 — intervention group
Group type: COMPARATOR
Intervention: JNJ-73763989 (various doses: 35, 100, 200, 300, or 400 mg for non-Japanese; 25, 100, or 200 mg for Japanese)
Number of subjects: 66
Study 33711782 — intervention group
Group type: EXPERIMENTAL
Intervention: pooled-dose MF/IND
Number of subjects: 10536
Study 33711782 — intervention group
Group type: COMPARATOR
Intervention: pooled-dose MF
Number of subjects: 10536
Study 33711782 — intervention group
Group type: EXPERIMENTAL
Intervention: pooled-dose MF/IND/GLY
Number of subjects: 10536
Study 33711782 — intervention group
Group type: EXPERIMENTAL
Intervention: high-dose MF/IND
Number of subjects: 10536
Study 33711782 — intervention group
Group type: COMPARATOR
Intervention: medium-dose MF/IND
Number of subjects: 10536
Study 33711782 — intervention group
Group type: EXPERIMENTAL
Intervention: high-dose MF/IND/GLY
Number of subjects: 10536
Study 33711782 — intervention group
Group type: COMPARATOR
Intervention: medium-dose MF/IND/GLY
Number of subjects: 10536
Study 33711782 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone/Salmeterol (F/S)
Number of subjects: 10536
Study 33711782 — intervention group
Group type: COMPARATOR
Intervention: F/S + Tiotropium (TIO)
Number of subjects: 10536
Study 35303013 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse group
Number of subjects: 75
Study 35303013 — intervention group
Group type: COMPARATOR
Intervention: Balance group
Number of subjects: 75
Study 32180150 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiannao Yizhi Formula (JYF)
Number of subjects: 60
Study 32180150 — intervention group
Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 60
Study 35982483 — intervention group
Group type: EXPERIMENTAL
Intervention: Olverembatinib (40 mg orally on alternate days for 28-day cycles)
Number of subjects: 165
Study 32862676 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA) - two doses of maximum 1 g each
Number of subjects: 81
Study 32862676 — intervention group
Group type: COMPARATOR
Intervention: Control - two doses of 50 ml 0.9% saline IV
Number of subjects: 81
Study 616782952 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision surgery combined with autologous corneal limbus stem cell transplantation
Number of subjects: 80
Study 616782952 — intervention group
Group type: COMPARATOR
Intervention: Pterygium excision surgery
Number of subjects: 80
Study 36114949 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 281
Study 36114949 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 281
Study 36114949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 34444838 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher potassium diet (100 mmol K/day)
Number of subjects: 29
Study 34444838 — intervention group
Group type: COMPARATOR
Intervention: Lower potassium diet (40 mmol K/day)
Number of subjects: 29
Study 35293030 — intervention group
Group type: EXPERIMENTAL
Intervention: apalutamide 240 mg
Number of subjects: 51
Study 35293030 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 51
Study 35090538 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 56
Study 35090538 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture treatment
Number of subjects: 56
Study 33611342 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes with ASD
Number of subjects: 435
Study 33611342 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 435
Study 33611342 — intervention group
Group type: EXPERIMENTAL
Intervention: Other neurodevelopmental disorders (ADHD, LD, co‐occurring ADHD/LD)
Number of subjects: 435
Study 33611342 — intervention group
Group type: EXPERIMENTAL
Intervention: Post‐concussion Symptom Scale (PCSS)
Number of subjects: 435
Study 35928723 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg LN18178
Number of subjects: 120
Study 35928723 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg LN18178
Number of subjects: 120
Study 35928723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 33518354 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 18% CP and probiotics (0.2 g/kg of diet from Lactobacillus acidophilus and Lactobacillus casei)
Number of subjects: 180
Study 33518354 — intervention group
Group type: COMPARATOR
Intervention: Diet containing 14% CP without probiotics
Number of subjects: 180
Study 32665344 — intervention group
Group type: EXPERIMENTAL
Intervention: Health4Life intervention (six web-based cartoon modules and accompanying activities delivered once per week for 6 weeks, and a smartphone application)
Number of subjects: 72
Study 32665344 — intervention group
Group type: EXPERIMENTAL
Intervention: Health4Life intervention
Number of subjects: 72
Study 32665344 — intervention group
Group type: COMPARATOR
Intervention: Active control (health education as usual)
Number of subjects: 72
Study 35025025 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol 2 g, 3-h infusion, q8h for 7-14 days
Number of subjects: 298
Study 35025025 — intervention group
Group type: COMPARATOR
Intervention: Meropenem 2 g, 3-h infusion, q8h for 7-14 days
Number of subjects: 298
Study 32622648 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Practitioners (NPs)
Number of subjects: 814
Study 32622648 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians (MDs)
Number of subjects: 814
Study 36309119 — intervention group
Group type: EXPERIMENTAL
Intervention: e-health supported intervention focusing on nutrition, exercise, and mental wellbeing, consisting of 4 face-to-face coaching sessions.
Number of subjects: 1075
Study 33307537 — intervention group
Group type: COMPARATOR
Intervention: Home-based pulmonary rehabilitation
Number of subjects: 73
Study 33307537 — intervention group
Group type: COMPARATOR
Intervention: Center-based pulmonary rehabilitation
Number of subjects: 73
Study 33307537 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based and center-based pulmonary rehabilitation
Number of subjects: 73
Study 35317821 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible low-dose antagonist (0.25 mg every other day, adjusted to 0.25 mg daily based on LH levels)
Number of subjects: 211
Study 35317821 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose antagonist (0.25 mg per day)
Number of subjects: 211
Study 35317821 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible low-dose antagonist
Number of subjects: 211
Study 35317821 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose antagonist
Number of subjects: 211
Study 33356418 — intervention group
Group type: EXPERIMENTAL
Intervention: Four courses of chemotherapy (including high-dose Ara-C)
Number of subjects: 1017
Study 33356418 — intervention group
Group type: COMPARATOR
Intervention: Three courses of chemotherapy
Number of subjects: 1017
Study 35673256 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth-delivered support group intervention (12 weeks)
Number of subjects: 31
Study 35673256 — intervention group
Group type: COMPARATOR
Intervention: Survey-only control group
Number of subjects: 31
Study 33739123 — intervention group
Group type: COMPARATOR
Intervention: Local heat (40-42°C applied with a heating pad over the abdomen for 2 hours)
Number of subjects: 34
Study 33739123 — intervention group
Group type: COMPARATOR
Intervention: Local heat (38°C applied with a water-perfused heating pad under the torso from 10 pm to 6 am)
Number of subjects: 34
Study 32350175 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of L-carnitine (LC)
Number of subjects: 11
Study 32350175 — intervention group
Group type: COMPARATOR
Intervention: 750 mg of L-carnitine (LC) + 50 g of carbohydrate (CHO)
Number of subjects: 11
Study 32350175 — intervention group
Group type: COMPARATOR
Intervention: 30 mg of CoQ10
Number of subjects: 11
Study 32350175 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of L-carnitine (LC)
Number of subjects: 11
Study 32350175 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of L-carnitine (LC) + 30 mg of CoQ10
Number of subjects: 11
Study 35073865 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAPS intervention (nurse-led proactive care management)
Number of subjects: 140
Study 35073865 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAPS intervention
Number of subjects: 140
Study 33151597 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 35
Study 33151597 — intervention group
Group type: COMPARATOR
Intervention: Conventional non-GLP-1-based therapy
Number of subjects: 35
Study 35503930 — intervention group
Group type: EXPERIMENTAL
Intervention: Active continuous theta burst stimulation (cTBS) to the primary motor cortex (PMC) and supplementary motor area (SMA)
Number of subjects: 35
Study 35503930 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation to either the PMC or SMA
Number of subjects: 35
Study 34718468 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab and etesevimab (700/1400 mg)
Number of subjects: 769
Study 34718468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 769
Study 32924891 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation intervention (five-week intervention integrating group-based activities and home-based activities)
Number of subjects: 0
Study 32307828 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching + web-based program
Number of subjects: 0
Study 32307828 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-only group
Number of subjects: 0
Study 32307828 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34645954 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG‐displayed HR assessment
Number of subjects: 51
Study 34645954 — intervention group
Group type: COMPARATOR
Intervention: ECG‐blinded HR assessment
Number of subjects: 51
Study 33219550 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical perfusion measurement with intraoperative laser speckle imaging and mean arterial blood pressure (MAP) recording
Number of subjects: 24
Study 35577602 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 U Ultra Rapid Lispro (URLi) administered subcutaneously into the abdomen
Number of subjects: 0
Study 35577602 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 U Ultra Rapid Lispro (URLi) administered subcutaneously into the upper arm
Number of subjects: 0
Study 35577602 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 U Ultra Rapid Lispro (URLi) administered subcutaneously into the thigh
Number of subjects: 0
Study 35577602 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) bolus administration of Ultra Rapid Lispro (URLi)
Number of subjects: 0
Study 33160921 — intervention group
Group type: COMPARATOR
Intervention: RMTMAP approach
Number of subjects: 75
Study 33160921 — intervention group
Group type: EXPERIMENTAL
Intervention: RMTP approach
Number of subjects: 75
Study 34515087 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile teledermoscopy with dermatologist review
Number of subjects: 199
Study 34515087 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile teledermoscopy services
Number of subjects: 199
Study 34515087 — intervention group
Group type: EXPERIMENTAL
Intervention: Teledermoscopy service (contingent valuation)
Number of subjects: 199
Study 32797175 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine prescribers
Number of subjects: 10871
Study 32797175 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone prescribers
Number of subjects: 10871
Study 33916252 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD)
Number of subjects: 30
Study 33916252 — intervention group
Group type: COMPARATOR
Intervention: Control group (general nutritional guidelines)
Number of subjects: 30
Study 32114812 — intervention group
Group type: EXPERIMENTAL
Intervention: Short intramedullary nail (175 mm)
Number of subjects: 229